BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM)(BCTXZ.US)

BriaCell Reports Extended Survival in Phase 2 Metastatic Breast Cancer Trial

BriaCell Therapeutics Corp. has reported positive Phase 2 clinical trial results for its Bria-IMT™ regimen in metastatic breast cancer patients. Out of 54 heavily pre-treated patients, 9 remain alive 18 to 47 months post-enrollment, surpassing survival benchmarks for standard therapies. The median overall survival for patients treated since 2022 was 15.6 months, with 52% surviving one year and 32% surviving two years. No treatment-related discontinuations were reported, and results will be confirmed in an ongoing Phase 3 study focusing on overall survival as the primary endpoint.

Stocks in Play: BriaCell Therapeutics Corp.

10:50 AM EST - BriaCell Therapeutics Corp. : Announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in nine cases as of their last assessment. BriaCell Therapeutics Corp. shares T.BCT are trading up $0.05 at $6.43.

BriaCell reports extended >18-47 months survival in Phase 2 metastatic breast cancer patients, with 9 cases surpassing 18 months.

Philadelphia and Vancouver, BC - On January 27, 2026, BriaCell Therapeutics Corp revealed encouraging Phase 2 survival data for their immunotherapies. The clinical-stage biotechnology company reported that several patients with metastatic breast cancer have exceeded the typical survival expectations, with 9 individuals surpassing the 18-month milestone in their latest evaluations. BriaCell's stock is listed under Nasdaq as BCTX, BCTXW, BCTXZ, BCTXL, and under TSX as BCT.

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

BriaCell Therapeutics Corp (NYSE:BCTX) has seen a significant rise in short interest, increasing by 174.82% to 281,000 shares, which is 14.95% of its float. This suggests a bearish sentiment among investors, as short selling indicates expectations of a price decline. The average time to cover short positions is 3.79 days. Compared to its peers, BriaCell's short interest is notably higher, with an average of 2.71% for similar companies. This trend may indicate growing caution among traders regarding the stock's performance.

BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0